Study: NCT00298025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide®
Description: Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagon ™
Description: Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Menopausal Gonadotropin (hMG)
Description: Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotropin (hMG)
Description: Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin (r-hCG)
Description: The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.